Neuroblastoma (NBL) is the most common extracranial solid cancer of childhood and is characterized by a remarkable biological heterogeneity, cause of mutiple genetic changes. The genetic profiles are the powerful tools for the clinical in risk stratification and choice of suitable treatment protocol in NBL patients. This will increase the chance of treatment's success and minimize the chemotherapy per patient. Sample: 6 NBL patients lower 18 months, non-amplified MYCN in National Children's Hospital. Method: The CGH technique is performed on the Agilent's system with the 400k chip. Results: 4 patients are found the numerical chromosomal aberations (NCA) (both stage L2), the others are the segmental chromosomal aberations (SCA) (1 stage L2 and 1 stage M). Based on this results, 4/5 patients will stop the chemotherapy, 1 patient continues the treatment. The stage M patient has the 50% chance of success in high-dose chemotherapy and stem cell transplantation. Conclusion: The genomic profile by CGH is established successfully in Vietnam, bring to NBL patients the higher chance of complete treatment with the minimal chemotherapy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.